marked.bio

Company

HUTCHMED

5 active trials that select patients by a biomarker on marked.bio, across 4 biomarkers; 3 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

HMPL-306 2savolitinib 1osimertinib 1HMPL-453 1

Trials

5 of 18 trials shown

  1. A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

    Recruiting Phase 3 HUTCHMED Started 2024Primary completion 2028-12 NCT06387069

    HMPL-306Salvage Chemotherapy Regimen

    Cohort 1: Patients with R/R primary AML harboring IDH1-R132 site mutation \[WHO 2022 Classification Criteria for Myeloid Neoplasms and Acute Leukemia…

    IDH1/2 mutationAcute Myeloid Leukemia

  2. Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

    Active, not recruiting Phase 3 HUTCHMED Started 2021Primary completion 2028-05 NCT05009836

    savolitinibosimertinib FDA EU

    …arrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI (i.e., exon 19 deletion, and L858R) and c-MET overexpression

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

  3. HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

    Recruiting Phase 2/3 HUTCHMED Started 2020Primary completion 2028-06 NCT04353375

    HMPL-453

    … or cytologically confirmed locally advanced unresectable or metastatic ICC patients with FGFR2 fusions/rearrangements/mutation (applicable to Cohort 1, Cohort 2 Stage II, Cohort 3 and Cohort 4…

    FGFR2 fusion or rearrangementAdvanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult

  4. Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

    Recruiting Phase 1 HUTCHMED Started 2025Primary completion 2026-12 NCT07025018

    HMPL-306

    Safety Lead-In Phase: Patients with gliomas of a documented IDH1 and/or IDH2 mutation.

    IDH1/2 mutationGliomas Harboring IDH1 and/or IDH2 Mutations

  5. A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

    Recruiting Phase 1 HUTCHMED Started 2024Primary completion 2027-10 NCT06387082

    HMPL-506

    3. 1\) Dose escalation phase: patient with MLL-rearranged and/or NPM1-mutant relapsed/refractory AML or ALL (confirmed as per the 2022 World Health Organization (WHO)…

    NPM1 mutationHematological Malignancies